No Data
No Data
Oppo Mai (688293): Rapid growth in 24Q1 medium revenue
Incident: The company released the 2023 report & 2024 quarterly report. In 2023, it achieved revenue of 243 million yuan (-17.4%), net profit of 54 million yuan (-48.7%), and deducted non-net profit of 34.72 million (-
OPM Biosciences' Shareholder to Cut Stake
Shenzhen Dachen Chuanglian Equity Investment Fund Partnership (Limited Partnership) plans to reduce its holdings in Shanghai OPM Biosciences (SHA:688293), the company said in a Thursday filing on the
Oppo Mai (688293): The medium business has entered a period of rapid growth
Matters: Opomax publishes its 2023 Annual Report and 2024 Quarterly Report. In 2023, the company achieved revenue of 243 million yuan, a year-on-year decrease of 17.4%, and net profit to mother of 54 million yuan, a year-on-year decrease of 48.7%.
Oppo Mai (688293): The medium business showed upward growth, and international expansion contributed to the company's performance growth
Incident Overview (1) Company Announcement 2023 Annual Report: 23 Achieved operating income of 243 million yuan for the full year, a year-on-year decrease of 17.41%, and realized net profit to mother of 54 million yuan, a year-on-year decrease of 48.72%, and realized a year-on-year decrease of 48.72%.
Express News | Oppo Mai: Dachen Chuanglian plans to reduce its shareholding by no more than 1.74%
Oppo Mai (688293): Sales revenue from the improved medium business increased significantly in the first quarter compared to the previous quarter
Core view Opmax's revenue for the full year of 2023 was 243 million yuan, a year-on-year decrease of 17.41%, mainly due to certain obstacles to the financing process of some biotech in '22, which led to a significant drop in CDMO revenue compared to last year
No Data